MJardin Group has announced a supply contract with ACA Müller ADAG Pharma Vertriebs GmbH, a subsidiary of Franchise Cannabis, for the supply offtake of a total of 2,250 kg of medical cannabis over a nine-month period in 2020 from MJardin’s 48,000 square foot Halifax facility (“AMI”)*. "ACA Müller has committed to purchase 250 kgs a month of high THC (>20%) medical cannabis flower during Q1 to Q3 2020 at a set price throughout the year," the team with the company explains. "AMI remains on track for EU GMP Certification by the end of this year and is expected to add an additional 20,000 square feet by Q1 2020."
“This agreement is a key milestone for MJardin and AMI as it represents our first sales outside of North America,” said Pat Witcher, COO of Mjardin. “Entering into the European market allows MJardin to achieve premium pricing in new markets for approximately half of the monthly production at AMI and is the beginning of building out a vital new geographic market for distribution. We look forward to working with Franchise as our European distribution partner in this high growth region.”
“MJardin has built a reputation as an operator with a top cultivation team. The Halifax facility is truly world class and fits with our strict quality standards. This supply relationship will allow us to increase our sales volumes to meet growing demand,” said Clifford Starke, Franchise Cannabis’s CEO. “The German market added 20,000 new patients last quarter, and our inventories are being sold out month after month. We look forward to working with AMI and MJardin as we continue to build market share across pharmacy networks in the jurisdiction with the highest price per gram in the world.”
“We are excited for this partnership with Franchise and what it will bring to MJardin and AMI. Connecting with European markets, in this industry, is a milestone for the Mi’kmaq of Nova Scotia and we look forward to furthering our international relationships,” said Chief Mike Sack, Assembly of Nova Scotia Mi’kmaw Chiefs.